T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment

Kevin Winthrop, Neil Korman, William Abramovits, Scott T. Rottinghaus, Huaming Tan, Annie Gardner, Geoffrey Mukwaya, Mandeep Kaur, Hernan Valdez

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Psoriasis is often treated with immunomodulatory therapies that can affect the immune response to common antigens. Tofacitinib is an oral Janus kinase inhibitor. Objective: To characterize the effect of long-term exposure to tofacitinib 10 mg twice daily on T-cell function in psoriasis patients. Methods: Patients completing at least 3 months' continuous treatment with tofacitinib 10 mg twice daily were vaccinated with T-cell–dependent vaccines (monovalent tetanus toxoid and 13-valent pneumococcal conjugate [PCV-13]). Patients were assessed at baseline (before vaccination) and then again 4 weeks after vaccination. For PCV-13, we evaluated serotype-specific, opsonophagocytic antibody responses, and for tetanus toxoid, we evaluated humoral responses. Results: Among 60 patients who completed the study, the geometric mean fold rise from baseline for the 13 PCV serotypes at 4 weeks postvaccination varied from 8.3 (serotype 3) to 101.9 (serotype 6A). Similar results were observed for patients with and without lymphopenia at baseline. For tetanus toxoid, 51 (88%) patients had ≥2-fold and 35 (60%) patients had ≥4-fold rise in antibody concentration. Limitations: There was no placebo control. Conclusion: Most psoriasis patients who receive tofacitinib can mount satisfactory T-cell–dependent responses to PCV-13 and tetanus vaccines.

Original languageEnglish (US)
JournalJournal of the American Academy of Dermatology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Tetanus Toxoid
Psoriasis
Therapeutics
Vaccination
Janus Kinases
Lymphopenia
Immunomodulation
tofacitinib
Antibody Formation
Vaccines
Placebos
T-Lymphocytes
Antigens
Serogroup
Antibodies

Keywords

  • immune response
  • Janus kinase inhibitor
  • pneumococcal vaccine
  • T cell
  • tetanus toxoid
  • tofacitinib

ASJC Scopus subject areas

  • Dermatology

Cite this

T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. / Winthrop, Kevin; Korman, Neil; Abramovits, William; Rottinghaus, Scott T.; Tan, Huaming; Gardner, Annie; Mukwaya, Geoffrey; Kaur, Mandeep; Valdez, Hernan.

In: Journal of the American Academy of Dermatology, 01.01.2018.

Research output: Contribution to journalArticle

Winthrop, Kevin ; Korman, Neil ; Abramovits, William ; Rottinghaus, Scott T. ; Tan, Huaming ; Gardner, Annie ; Mukwaya, Geoffrey ; Kaur, Mandeep ; Valdez, Hernan. / T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. In: Journal of the American Academy of Dermatology. 2018.
@article{f324342a6f0c4eb5b81d63588355fdea,
title = "T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment",
abstract = "Background: Psoriasis is often treated with immunomodulatory therapies that can affect the immune response to common antigens. Tofacitinib is an oral Janus kinase inhibitor. Objective: To characterize the effect of long-term exposure to tofacitinib 10 mg twice daily on T-cell function in psoriasis patients. Methods: Patients completing at least 3 months' continuous treatment with tofacitinib 10 mg twice daily were vaccinated with T-cell–dependent vaccines (monovalent tetanus toxoid and 13-valent pneumococcal conjugate [PCV-13]). Patients were assessed at baseline (before vaccination) and then again 4 weeks after vaccination. For PCV-13, we evaluated serotype-specific, opsonophagocytic antibody responses, and for tetanus toxoid, we evaluated humoral responses. Results: Among 60 patients who completed the study, the geometric mean fold rise from baseline for the 13 PCV serotypes at 4 weeks postvaccination varied from 8.3 (serotype 3) to 101.9 (serotype 6A). Similar results were observed for patients with and without lymphopenia at baseline. For tetanus toxoid, 51 (88{\%}) patients had ≥2-fold and 35 (60{\%}) patients had ≥4-fold rise in antibody concentration. Limitations: There was no placebo control. Conclusion: Most psoriasis patients who receive tofacitinib can mount satisfactory T-cell–dependent responses to PCV-13 and tetanus vaccines.",
keywords = "immune response, Janus kinase inhibitor, pneumococcal vaccine, T cell, tetanus toxoid, tofacitinib",
author = "Kevin Winthrop and Neil Korman and William Abramovits and Rottinghaus, {Scott T.} and Huaming Tan and Annie Gardner and Geoffrey Mukwaya and Mandeep Kaur and Hernan Valdez",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jaad.2017.09.076",
language = "English (US)",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment

AU - Winthrop, Kevin

AU - Korman, Neil

AU - Abramovits, William

AU - Rottinghaus, Scott T.

AU - Tan, Huaming

AU - Gardner, Annie

AU - Mukwaya, Geoffrey

AU - Kaur, Mandeep

AU - Valdez, Hernan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Psoriasis is often treated with immunomodulatory therapies that can affect the immune response to common antigens. Tofacitinib is an oral Janus kinase inhibitor. Objective: To characterize the effect of long-term exposure to tofacitinib 10 mg twice daily on T-cell function in psoriasis patients. Methods: Patients completing at least 3 months' continuous treatment with tofacitinib 10 mg twice daily were vaccinated with T-cell–dependent vaccines (monovalent tetanus toxoid and 13-valent pneumococcal conjugate [PCV-13]). Patients were assessed at baseline (before vaccination) and then again 4 weeks after vaccination. For PCV-13, we evaluated serotype-specific, opsonophagocytic antibody responses, and for tetanus toxoid, we evaluated humoral responses. Results: Among 60 patients who completed the study, the geometric mean fold rise from baseline for the 13 PCV serotypes at 4 weeks postvaccination varied from 8.3 (serotype 3) to 101.9 (serotype 6A). Similar results were observed for patients with and without lymphopenia at baseline. For tetanus toxoid, 51 (88%) patients had ≥2-fold and 35 (60%) patients had ≥4-fold rise in antibody concentration. Limitations: There was no placebo control. Conclusion: Most psoriasis patients who receive tofacitinib can mount satisfactory T-cell–dependent responses to PCV-13 and tetanus vaccines.

AB - Background: Psoriasis is often treated with immunomodulatory therapies that can affect the immune response to common antigens. Tofacitinib is an oral Janus kinase inhibitor. Objective: To characterize the effect of long-term exposure to tofacitinib 10 mg twice daily on T-cell function in psoriasis patients. Methods: Patients completing at least 3 months' continuous treatment with tofacitinib 10 mg twice daily were vaccinated with T-cell–dependent vaccines (monovalent tetanus toxoid and 13-valent pneumococcal conjugate [PCV-13]). Patients were assessed at baseline (before vaccination) and then again 4 weeks after vaccination. For PCV-13, we evaluated serotype-specific, opsonophagocytic antibody responses, and for tetanus toxoid, we evaluated humoral responses. Results: Among 60 patients who completed the study, the geometric mean fold rise from baseline for the 13 PCV serotypes at 4 weeks postvaccination varied from 8.3 (serotype 3) to 101.9 (serotype 6A). Similar results were observed for patients with and without lymphopenia at baseline. For tetanus toxoid, 51 (88%) patients had ≥2-fold and 35 (60%) patients had ≥4-fold rise in antibody concentration. Limitations: There was no placebo control. Conclusion: Most psoriasis patients who receive tofacitinib can mount satisfactory T-cell–dependent responses to PCV-13 and tetanus vaccines.

KW - immune response

KW - Janus kinase inhibitor

KW - pneumococcal vaccine

KW - T cell

KW - tetanus toxoid

KW - tofacitinib

UR - http://www.scopus.com/inward/record.url?scp=85042661818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042661818&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2017.09.076

DO - 10.1016/j.jaad.2017.09.076

M3 - Article

C2 - 29080806

AN - SCOPUS:85042661818

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

ER -